Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLR NYSEAMERICAN:AZTR NASDAQ:EDSA NASDAQ:FLGC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLRAllarity Therapeutics$1.00-0.3%$0.96$0.61▼$7.38$15.03M0.041.14 million shs211,551 shsAZTRAzitra$0.23-0.2%$0.27$0.22▼$12.00$3.91M-1.593.22 million shs618,604 shsEDSAEdesa Biotech$2.41+1.5%$2.02$1.55▼$5.59$16.88M0.39491,741 shs19,691 shsFLGCFlora Growth$0.62-1.7%$0.67$0.42▼$2.11$14.01M1.97274,000 shs173,169 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLRAllarity Therapeutics0.00%-7.41%+21.07%+6.38%-83.66%AZTRAzitra-3.76%-9.94%-13.79%-20.18%-92.57%EDSAEdesa Biotech+4.87%+14.49%+17.91%+4.87%-49.47%FLGCFlora Growth-1.31%-10.04%-12.36%+17.18%-42.64%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALLRAllarity Therapeutics0.6576 of 5 stars0.02.00.00.02.90.01.3AZTRAzitraN/AN/AN/AN/AN/AN/AN/AN/AEDSAEdesa Biotech2.2151 of 5 stars2.05.00.00.03.31.70.6FLGCFlora Growth2.5108 of 5 stars3.33.00.00.03.30.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLRAllarity Therapeutics 0.00N/AN/AN/AAZTRAzitra 0.00N/AN/AN/AEDSAEdesa Biotech 4.00Strong Buy$5.00107.90% UpsideFLGCFlora Growth 2.50Moderate Buy$4.00544.64% UpsideCurrent Analyst Ratings BreakdownLatest AZTR, EDSA, FLGC, and ALLR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/27/2025EDSAEdesa BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$5.00(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLRAllarity TherapeuticsN/AN/AN/AN/A$1.62 per shareN/AAZTRAzitra$10K391.12N/AN/A$0.75 per share0.30EDSAEdesa BiotechN/AN/AN/AN/A$0.61 per shareN/AFLGCFlora Growth$59.51M0.24N/AN/A$0.31 per share2.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLRAllarity Therapeutics-$24.51MN/A0.00N/AN/AN/A-147.94%-90.33%8/4/2025 (Estimated)AZTRAzitra-$8.97MN/A0.00N/AN/AN/A-183.05%-135.21%8/11/2025 (Estimated)EDSAEdesa Biotech-$6.17M-$1.59N/AN/AN/AN/A-187.01%-78.72%8/8/2025 (Estimated)FLGCFlora Growth-$15.91M-$0.98N/AN/AN/A-24.85%-216.49%-45.56%8/11/2025 (Estimated)Latest AZTR, EDSA, FLGC, and ALLR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025N/AAZTRAzitra-$0.21N/AN/AN/AN/AN/A8/11/2025Q2 2025FLGCFlora Growth-$0.06N/AN/AN/A$11.77 millionN/A8/8/2025N/AEDSAEdesa Biotech-$0.23N/AN/AN/AN/AN/A5/14/2025Q2 2025EDSAEdesa Biotech-$0.30-$0.30N/A-$0.30N/AN/A5/13/2025Q1 2025ALLRAllarity Therapeutics-$8.10-$0.25+$7.85-$0.25N/AN/A5/13/2025Q1 2025FLGCFlora Growth-$0.01-$0.04-$0.03-$0.04$14.79 million$11.79 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALLRAllarity TherapeuticsN/AN/AN/AN/AN/AAZTRAzitraN/AN/AN/AN/AN/AEDSAEdesa BiotechN/AN/AN/AN/AN/AFLGCFlora GrowthN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLRAllarity TherapeuticsN/A2.662.66AZTRAzitraN/A3.033.03EDSAEdesa BiotechN/A15.7215.72FLGCFlora Growth0.881.050.67Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLRAllarity Therapeutics11.53%AZTRAzitra11.16%EDSAEdesa Biotech5.50%FLGCFlora Growth36.01%Insider OwnershipCompanyInsider OwnershipALLRAllarity Therapeutics0.08%AZTRAzitra0.25%EDSAEdesa Biotech22.60%FLGCFlora Growth12.56%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLRAllarity Therapeutics1015.08 million15.07 millionNot OptionableAZTRAzitra1017.23 million17.18 millionNot OptionableEDSAEdesa Biotech207.02 million5.44 millionNot OptionableFLGCFlora Growth28022.57 million19.73 millionNot OptionableAZTR, EDSA, FLGC, and ALLR HeadlinesRecent News About These CompaniesFlora Growth Corp. Announces Shareholder Meeting Results and Strategic ApprovalsJuly 2, 2025 | theglobeandmail.comFlora Growth Corp. (FLGC) Income Statement - Yahoo FinanceJuly 1, 2025 | finance.yahoo.comFlora Growth Corp.: Flora Growth Announces Results of 2025 Annual and Special Meeting of ShareholdersJune 30, 2025 | finanznachrichten.deFlora Growth Announces Results of 2025 Annual and Special Meeting of ShareholdersJune 30, 2025 | newsfilecorp.comNFlora Growth Corporation Registered ShsJune 21, 2025 | markets.businessinsider.comFlora Growth Corp Invests in Ethereum, Solana, Sui and RippleMay 6, 2025 | investing.comFlora Enters Crypto Space with Strategic Investments in Ethereum, Solana, Sui and RippleMay 6, 2025 | stockhouse.comFlora Growth Corp announces investment in cryptocurrencies and blockchainMay 5, 2025 | msn.comFlora Growth Corp.: Flora Enters Crypto Space with Strategic Investments in Ethereum, Solana, Sui and RippleMay 5, 2025 | finanznachrichten.deFlora Growth Ventures into Cryptocurrency with Strategic InvestmentsMay 5, 2025 | tipranks.comFlora Growth Corp. Reports 2024 Financial ResultsApril 1, 2025 | tipranks.comFlora Growth sees revenue drop across all businesses in 2024March 25, 2025 | greenmarketreport.comGFlora Growth Corp. Reports 2024 Financial ResultsMarch 24, 2025 | newsfilecorp.comNFlora Growth files to sell 3.21M common shares for holdersFebruary 24, 2025 | markets.businessinsider.comFlora Growth hires innovation leader for Vessel brandFebruary 11, 2025 | msn.comFlora Announces Appointment of Patrick Moloney as Head of Product Development for VesselFebruary 11, 2025 | newsfilecorp.comNFlora Growth stock hits 52-week low at $0.74 amid market challengesJanuary 29, 2025 | msn.comClifford Starke's Holdings in Flora Growth Corp.December 17, 2024 | newsfilecorp.comNWhat’s Causing Flora Growth Corp (FLGC) Stock’s 18.18% Jump Over the Last Six Months?December 17, 2024 | bovnews.comBFlora Growth Raises $3.6 Million in Stock OfferingDecember 16, 2024 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAZTR, EDSA, FLGC, and ALLR Company DescriptionsAllarity Therapeutics NASDAQ:ALLR$1.00 0.00 (-0.34%) Closing price 04:00 PM EasternExtended Trading$1.01 +0.01 (+1.34%) As of 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.Azitra NYSEAMERICAN:AZTR$0.23 0.00 (-0.22%) Closing price 04:10 PM EasternExtended Trading$0.22 0.00 (-1.32%) As of 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Azitra, Inc., an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.Edesa Biotech NASDAQ:EDSA$2.40 +0.04 (+1.48%) Closing price 03:58 PM EasternExtended Trading$2.40 0.00 (0.00%) As of 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.Flora Growth NASDAQ:FLGC$0.62 -0.01 (-1.66%) Closing price 04:00 PM EasternExtended Trading$0.63 +0.01 (+1.69%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide. It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products. It also offers food and beverage, nutraceuticals, cannabis accessories and technology, personal care, and wellness; cannabidiol (CBD) derived products, such as gummies, topicals, tinctures, and vape products; cannabis consumption accessories, personal storage, and travel accessories for the vape and dry herbs. In addition, the company manufactures and distributes pharmaceutical goods and medical cannabis products to treat a variety of health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants. The company sells its products under the JustCBD, Vessel, and Phatebo brands. Flora Growth Corp. was incorporated in 2019 and is based in Fort Lauderdale, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield How Goldman Sachs Earnings Help You Strategize Your Portfolio Is Amazon Really the Best Forever Stock for Your Portfolio? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
